Atea Pharmaceuticalsincis A Clinical Stage Biopharmaceutical Company Based In Bostonmassachusettsfounded In 2014The Company Is Dedicated To Developing Innovative Oral Antiviral Therapies To Address Unmet Medical Needsparticularly For Serious Viral Diseases Such As Hepatitis C And Dengueatea Utilizes Its Expertise In Medicinal Chemistry And Virology To Advance Antiviral Science The Company S Product Pipeline Includes Bemnifosbuvirat 527 A Purine Nucleotide Prodrug Initially Developed For Covid 19And A Combination Therapy Of Bemnifosbuvir With Ruzasvir For Treating Hepatitis Catea Focuses On Creating Orally Available Antiviral Agentsaiming To Transform The Treatment Landscape For Severe Viral Infections Atea Pharmaceuticals Is Committed To Fostering A Diverse And Inclusive Workforce And Actively Supports Community Programs Related To Medical And Humanitarian Aidthe Company Has A Strong Financial Positionwith Approximately $578 Million In Cash And Marketable Securities As Of Q3 2024Allowing It To Fund Its Clinical Programs Effectively
